No sur­prise: Ab­b­Vie turns cold shoul­der to a messy rheuma­toid arthri­tis part­ner­ship with Abl­ynx

Ab­b­Vie is punt­ing yet an­oth­er high-pro­file rheuma­toid arthri­tis de­vel­op­ment part­ner­ship. The phar­ma out­fit is tak­ing a pass on Abl­ynx’s Phase III-ready drug vo­bar­il­izum­ab and shrug­ging off its $175 mil­lion up­front buy-in.

The de­ci­sion will come as no sur­prise to any care­ful ob­serv­er of RA. The an­ti-IL-6R re­cent­ly failed to pass muster in a Phase IIb tri­al, de­spite Abl­ynx’s best ef­forts to get an­a­lysts to look past the fail­ure on the pri­ma­ry end­point and on to more up­beat re­sults in the study. And Ab­b­Vie al­ready has an in-house ri­val that it’s been much more pumped about.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.